

Curriculum Vitae

Date of preparation: February 13, 2017

Name: Shilpa Joshi Desai, MD

Current Position: July 7, 2015-July 6, 2017
Surgical Retina Fellow
New England Eye Center/Ophthalmic Consultants of Boston
Boston, MA

Future Position: July 6, 2017 -
Assistant Professor of Ophthalmology
New England Eye Center at Tufts Medical Center
Boston, MA

Office Address: 800 Washington Street
Boston, MA 02111
Cell: (908) 347-0428
Email: sdesai3@tuftsmedicalcenter.org

Home Address: 185 Massachusetts Avenue, Apt 403
Boston, MA 02115

Date of Birth: 4/22/1985
Place of Birth: Rochester, NY
Citizenship: USA

EDUCATION

9/2003-6/2007	Massachusetts Institute of Technology	B.S., Chemical Engineering GPA: 5.0/5.0
8/2007-5/2011	Harvard Medical School	M.D. <i>cum laude</i>

HONORS & AWARDS

2004	Supply Chain Excellence Award, Johnson and Johnson
2005	Tau Beta Pi Member, Engineering Honor Society
2007	Phi Beta Kappa, Academic Honor Society
2008	Paul and Daisy Soros Fellowship Semi-Finalist
2010	Elected Member of Aescupalian Club, Harvard Medical School
2014	Garcia/Asbury Clinical Research Award
2016	National Eye Institute Travel Grant Recipient, ARVO 2016

KEYWORDS/AREAS OF INTEREST

Ophthalmology, Retina, Development

PROFESSIONAL ACTIVITIES

CLINICAL

2015-2017 Surgical Retina Fellow, Ophthalmic Consultants of Boston/New England Eye Center, Boston, MA

2012-2015 Resident, Ophthalmology, University of California, San Francisco, CA

2011-2012 Medical Internship, Mount Auburn Hospital, Cambridge, MA

2007-2011 Medical Student, Harvard Medical School: High Honors in Ophthalmology, Surgery, Ob/Gyn, Pediatrics, Neurology, Emergency Medicine, and Medicine Sub-Internship.

2011 Clinical Volunteer, H.V. Desai Eye Hospital. Shadowed physicians in Eye Hospital outside Pune, India. Took histories, did clinical exams, reviewed studies, observed in operating room.

RESEARCH

2015 Sub-Investigator, Ophthalmic Consultants of Boston

PRO-CON VGFTe-AMD-1507 – A prospective, single-blind, randomized study to evaluate intravitreal aflibercept injection versus sham as prophylaxis against conversion to neovascular age-related macular degeneration in high risk eyes

CNT02476MDG2002- A phase 2b, multicenter, double-masked, randomized study evaluating the safety and clinical response of sub-retinal administration of CNT0 2476 in subjects with visual acuity impairment associated with geographic atrophy secondary to age related macular degeneration

FILLY – POT-CP121614 – A phase II, multicenter, randomized, single-masked, sham-controlled study of safety, tolerability, and evidence of activity of intravitreal APL-2 therapy in patients with geographic atrophy

NT-503-3-AMD-001 – A multi-center, two-stage, open-label phase I and randomized, active controlled, masked phase II study to evaluate the safety and efficacy of intravitreal implantation of NT-503-3 encapsulated cell technology compared with Eylea for the treatment of recurrent sub-foveal choroidal neovascularization secondary to age related macular degeneration

EGP-437-007 – Open-label, multi-center, phase 1b/2a clinical trial designed to evaluate the safety and efficacy of iontophoretic dexamethasone phosphate ophthalmic solution in patients with macular edema

CAPELLA – R2176-3-AMD-1417 – A phase 2, double-masked, randomized, controlled, multiple-dose, regimen-ranging study of the efficacy and safety of intravitreal REGN2176-3 in patients with neovascular age-related macular degeneration

DS7080-A-U101 – Phase I dose escalation and exploration study of DS-7080a in patients with neovascular age-related macular degeneration

VIDI 8232-CL 3001- A phase 2, double-masked, randomized, active controlled study to evaluate the efficacy and safety of ASP8232 in reducing central retinal thickness in subjects with diabetic macular edema

OPH1002 – A phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista ® (anti-PDGF-B pegylated aptamer) administration in combination with Lucentis® compared to Lucentis ® monotherapy in subjects with subfoveal neovascular age-related macular degeneration

OPH1004 – A phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista ® (anti-PDGF-B pegylated aptamer) administration in combination with either Avastin ® or Eylea ® compared to Avastin ® or Eylea ® monotherapy in subjects with subfoveal neovascular age-related macular degeneration

OPH1005 – Sub-retinal fibrosis in neovascular AMD: A 24 month phase 2a open label safety study of Fovista ® (Anti-PDGF-BB pegylated aptamer) regimen administered independently or in combination with anti-VEGF therapy (Avastin ®, or Eylea ®) during the induction and maintenance phases of therapy

OPH1006 – Effect of anti-VEGF agents administered on a quarterly maintenance regimen in neovascular AMD subjects receiving anti-PDGF therapy: An 18 month phase 2a Open Label, randomized study of Avastin®, Lucentis®, or Eylea® (anti-VEGF therapy) administered in combination with Fovista® (Anti-PDGF-BB pegylated aptamer in neovascular AMD subjects)

CHROMA GX29176 – A phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration.

STOMP-CSC – Short-term oral mifepristone for central serous chorioretinopathy: A placebo-controlled dose ranging study of mifepristone for CSC.

R910-OD-1403 – An open-label, dose-escalation study of the safety and tolerability of intravitreal REGN910-3 and IVT REGN910 in patients with either neovascular AMD or DME.

VMA-001 – A safety and efficacy assessment of resolveine for treatment of vitreomacular attachment.

ORBIT – TG-MV-019 – Ocriplasmin research to better inform treatment.

ACU-4429-202 – A multicenter, randomized, double masked, placebo-controlled, dose-escalation, multiple-dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ACU-4429 in subjects with dry age-related macular degeneration.

MAHALO EXT – A phase 1B/II, multicenter, randomized, single-masked, sham injection controlled study of safety, tolerability, and evidence of activity of FCFD4514G intravitreal injections administered monthly or bi-monthly to subjects with geographic atrophy.

YAG-001 – A single-center, prospective study evaluating safety and efficacy of YAG vitreolysis versus sham for symptomatic Weiss ring due to PVD.

YAG-001 – A single-center, open-label, prospective study evaluating the safety and efficacy of YAG vitreolysis for symptomatic vitreous floaters.

2010 Research Assistant, Massachusetts Eye and Ear Institute. Clinical study on effect of caffeine on intra-ocular pressure. (Mentor – Dr. Louis Pasquale)

2009 Research Assistant, Orthopedics Department, Children’s Hospital Boston. Anterior cruciate ligament healing through the use of collagen scaffolds. (Mentor – Dr. Martha Murray)

2006 Research Assistant, Department of Chemical Engineering, MIT. Targeted, stimuli-responsive polymeric drug delivery. (Mentor – Dr. Jackie Ying)

2004 Research Assistant, Department of Chemical Engineering, MIT. Cell patterning and microfluidic channels. (Mentor – Dr. Robert Langer)

PROFESSIONAL ORGANIZATIONS

Service to Professional Organizations

2012-2015	Membership Advisory Committee, American Academy of Ophthalmology
2009-2010	Fellow, Intersociety Multicultural Fellows Committee, Harvard Medical School
2007-2008	Executive Board, John Warren Surgical Society, Harvard Medical School

TEACHING AND MENTORING

2014	Morbidity and Mortality Panelist in Internal Medicine: Branch Retinal Artery Occlusion, Mt Zion Hospital: July 25, 2014
2014	Morbidity and Mortality Panelist in Internal Medicine: Orbital Granulomatosis and Polyangiitis, UCSF: July 9, 2014
2013	Morbidity and Mortality Panelist in Internal Medicine: Oncology Case Presentation. San Francisco, UCSF: May 22, 2013
2013	Morbidity and Mortality Panelist in Internal Medicine: Neurosyphilis. San Francisco, UCSF: March 6, 2013

2011-2012	Non-resident Tutor, Harvard University, Winthrop Hall. Cambridge, MA.
2010-2011	Tutor, Patient Doctor II. Harvard Medical School, Boston, MA.
2008-2009	Resident Advisor. Vanderbilt Hall, Harvard Medical School, Boston, MA.
2006-2007	Teaching Assistant, Introductory Biology. MIT, Cambridge MA.
2005-2007	Tutor, Chemical Engineering. MIT, Cambridge MA.

PRESENTATIONS

2015	ARVO Women in Retina Luncheon: Fellow Eye Comparisons in SEVEN-UP Study. Denver, CO: May 3, 2015
2014	Internal Medicine Noon Conference: Inpatient Ophthalmology Consultation, UCSF: August 1, 2014
2014	Alexander R. Irvine Residents' Day: Fungemia and Fungal Endophthalmitis, UCSF: April 10, 2014
2014	Pacific Retina Club: Neurosyphilis, Grand Hyatt San Francisco: March 29, 2014
2014	Grand Rounds Presenter in Ophthalmology: Crack Cocaine Keratitis, UCSF: March 13, 2014
2014	Grand Rounds Presenter in Ophthalmology: Acute Macular Neuro-retinitis, UCSF: February 27, 2014
2014	Grand Rounds Presenter in Ophthalmology: UGH syndrome, UCSF: January 30, 2014
2014	Grand Rounds Presenter in Ophthalmology: Brown's Syndrome, UCSF: January 16, 2014
2013	Grand Rounds Presenter in Ophthalmology: Levator Palsy in Neurosurgical Patients, UCSF: October 24, 2013
2013	Grand Rounds Presenter in Ophthalmology: Leukemic Uveitis. San Francisco, UCSF: April 25, 2013
2013	Grand Rounds Presenter in Ophthalmology: Neurosyphilis. San Francisco, UCSF: January 17, 2013
2012	Grand Rounds Presenter in Ophthalmology: Choroidal Melanoma. San Francisco, UCSF: November 29, 2012.
2012	Grand Rounds Presenter in Ophthalmology: Sino-orbital Mucormycosis. San Francisco, UCSF: November 1, 2012.
2011	Grand Rounds Presenter in Medicine: Neisseria Meningitidis Pericarditis. Cambridge, MA. Mount Auburn Hospital: November 10, 2011.

PUBLICATIONS

1. Heier JS, Kherani S, **Desai SJ** et al. Intravitreal injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. *The Lancet*. 2017 (Online First).
2. **Desai SJ**, Chen X, Heier JS. Chapter "Retinal Vein Occlusion" Yanoff and Duker Ophthalmology 5th Edition. Elsevier Publishing, 2017.
3. **Desai SJ** and Yasin Alibhai. Chapter "Angioid Streaks" The Retina Atlas 3rd Edition. Elsevier Publishing, 2017.
4. **Desai SJ** and Yasin Alibhai. Chapter "Cone Dystrophy" The Retina Atlas 3rd Edition. Elsevier Publishing, 2017.
5. **Desai SJ** and Yasin Alibhai. Chapter "Isolated CME" The Retina Atlas 3rd Edition. Elsevier Publishing 2017.
6. **Desai SJ** and Yasin Alibhai. Chapter "Retinitis Pigmentosa" The Retina Atlas 3rd Edition. Elsevier Publishing 2017.

7. **Desai SJ** and Yasin Alibhai. Chapter “Vitelliform Dystrophy” The Retina Atlas 3rd Edition. Elsevier Publishing 2017.
8. **Desai SJ**, Reichel E. Future Treatment in Wet AMD. Current Ophthalmology Reports. Accepted.
9. **Desai SJ**, Bauman C. Chapter “Retinal Vein Occlusion” Anti-VEGF Use in Ophthalmology. SLACK publishing, 2016.
10. Bhisitkul R, **Desai SJ**, Boyer D, Sadda SR, Zhang K. Fellow eye comparisons for 7-year outcomes in ranibizumab-treated AMD subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study). Ophthalmology. 2016. 123(6): 1269-77.
11. **Desai SJ**, Heier JS. Retained Intra-Ocular Air. JAMA Ophthalmology. 2016. 134(7): 842-843.
12. **Desai SJ**, Lauer N, Geske MJ, Jeng BH, Bloomer MM, Vagefi MR. Local and Regional Spread of Primary Conjunctival Squamous Cell Carcinoma. Eye & Contact Lens. 16 April 2016
13. **Desai SJ**, Lawton MT, McDermott MW, Horton JC. Vertical Gaze Limitation and Ptosis from Removal of the Orbital Roof during Pterional Craniotomy. Ophthalmology. 2015. 122(3): 631-638.
14. **Desai SJ**, Kim HJ, Kersten RC, Bloomer MM, Vagefi MR. Extra-scleral spread of choroidal melanoma via Tantalum Marker Suture Track. JAMA Ophthalmology. 2013 Dec; 131(12): 1643-5.
15. Gorovoy I, **Desai SJ**. Syphilitic posterior placoid chorioretinitis. Sexually Transmitted Diseases. 2013. 40(11): 852-853.
16. **Desai SJ**, Julian K. Blurred Vision. UCSF Outpatient Medicine Handbook. AgileMD. Palo Alto. 2013.
17. **Desai SJ** and Martha Murray. Graduate Thesis: Functional and Histologic Healing of the Porcine Anterior Cruciate Ligament Enhanced by Collagen-Platelet Composite. Harvard Medical School. 2011.
18. **Joshi SM**, Mastrangelo AN, Magarian EM, Fleming BC, Murray MM. Collagen-Platelet Composite Enhances Biomechanical and Histologic Healing of the Porcine Anterior Cruciate Ligament. American Journal of Sports Medicine. 2009. 37(12): 2401 – 2410.
19. Vavken P, **Joshi SM**, Murray MM. Fibrin concentration affects ACL fibroblast proliferation and collagen synthesis. The Knee. 2010. 18(1): 42 – 46.
20. Vavken P, **Joshi SM**, Murray MM. Triton-X is the most effective among three decellularization agents for ACL tissue engineering. Journal of Orthopaedic Research. 2009. 27(12): 1612 – 1618.
21. **Joshi, SM**. Acknowledgement, Chapter 24 “Tissue Engineering of Ligaments and Tendons” in Fundamentals of Tissue Engineering and Regenerative Medicine. Springer, 2009.

ABSTRACTS

1. **Desai SJ**, Chen X, Duker JS. Unilateral White Spot. ASRS 2017 Annual Meeting. (Boston, MA, 2017)
2. **Desai SJ**, Novais E, Sanayei N, Cole E, Louzada R, Fugimoto J, Bauman CR, Duker JS, Waheed NK. “Choriocapillaris changes on OCT Angiography after Anti-VEGF injection in exudative age related macular degeneration” New England Ophthalmic Society (Boston, MA 2016)
3. **Desai SJ**, Novais E, Sanayei N, Cole E, Louzada R, Fugimoto J, Bauman CR, Duker JS, Waheed NK. “Choriocapillaris changes on OCT Angiography after Anti-VEGF injection in exudative age related macular degeneration” ARVO 2016 Annual Meeting (Seattle, WA, 2016)
4. **Desai SJ**, Bhisitkul RB, Rofagha S, Enanoria W, Boyer D, Sadda SR, Zhang K. “Fellow Eye Comparisons for 7-year vision outcomes in Ranibizumab-treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP). ARVO 2015 Annual Meeting (Denver, CO, 2015).
5. **Desai SJ**, Lawton MT, McDermott MW, Horton JC. “Vertical Gaze Limitation and Ptosis from Removal of the Orbital Roof during Pterional Craniotomy” ARVO 2014 Annual Meeting (Orlando, FL, 2014)
6. **Desai SJ**, Schallhorn J, Schallhorn S, Ou Y. “Intraocular Pressure and Central Corneal Thickness in 91,000 Refractive Surgery Patients” ARVO 2013 Annual Meeting, (Seattle, WA, 2013)

7. **Joshi, SM**, Mastrangelo, AN, Murray, MM “Collagen-Platelet Composite Enhances Histologic Healing of the ACL” ORS 55th Annual Meeting, (Las Vegas, NV, 2009)
8. **Joshi SM**, Mastrangelo AN, and Murray MM. “Collagen-Platelet Composite Enhances Histologic Healing of the ACL.” Center for Integration of Medicine & Innovative Technology Congress (Boston, MA, 2008)
9. Vavken, P, **Joshi SM**, Murray, MM. “Decellularized porcine anterior cruciate ligament as a biomaterial for ACL tissue engineering.” ORS 55th Annual Meeting (Las Vegas, NV, 2009)
10. Vavken P, **Joshi SM**, Murray MM. “Decellularized porcine anterior cruciate ligament as a biomaterial for ACL tissue engineering.” Center for Integration of Medicine & Innovative Technology Congress (Boston, MA, 2008)
11. Vavken P, **Joshi SM**, Murray MM. “ACL fibroblast proliferation and biosynthesis are attenuated by high fibrin concentration.” Center for Integration of Medicine & Innovative Technology Congress (Boston, MA, 2008)
12. Zaman NT, Tan FE, **Joshi SM**, Ying JY. “Targeted Stimuli-Responsive Dextran Conjugates for Doxorubicin Delivery to Hepatocytes.” MIT-Singapore Alliance. (Singapore; Boston, MA, 2006)